# A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome

> **NCT00630370** · PHASE2 · TERMINATED · sponsor: **Procter and Gamble** · enrollment: 6 (actual)

## Conditions studied

- Post Prandial Distress Syndrome

## Interventions

- **DRUG:** Placebo
- **DRUG:** 20 mg ATI 7505
- **DRUG:** 40 mg ATI 7505
- **DRUG:** 80 mg ATI 7505

## Key facts

- **NCT ID:** NCT00630370
- **Lead sponsor:** Procter and Gamble
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2009-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630370, "A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00630370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*